• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Identifying risk factors for endophthalmitis after cataract surgery


An elevated risk may be associated with the cataract type, case complexity, and history of diabetic macular edema or proliferative diabetic retinopathy.

Identifying risk factors for endophthalmitis after cataract surgery

The overall incidence of endophthalmitis was 0.633 case per 1,000 surgeries.

A large retrospective analysis recently set out to identify the risk factors for endophthalmitis after cataract surgery.

This study, conducted by Michael H. Goldstein, MD, president of Ocular Therapeutix, Inc., and colleagues, used the IRIS Registry. They reported that complex cataract procedures, the performance of simultaneous vitreous procedures, a history of diabetic macular edema or proliferative diabetic retinopathy, male sex, and certain cataract types were associated with significantly higher rates of endophthalmitis.

The investigators also determined if use of the ReSure Sealant impacted the incidence rate of endophthalmitis either way. This hydrogel sealant creates an in situ temporary soft surface barrier to prevent wound leaks from clear corneal incisions up to 3.5 mm in size following cataract surgery.

The investigators compared the incidence of endophthalmitis within 30 days of any cataract procedures performed with and without the ReSure Sealant and the incidence of endophthalmitis within 30 days after any cataract surgery performed in the US.

This study included patients who underwent cataract surgery from January 1, 2016, to December 1, 2019. All patients underwent phacoemulsification with intraocular lens implantation and had completed 1 or more visits within 30 days postoperatively.

Data from more than 6,700,000 eyes (4.1 million patients; 58.9% women; mean age, 70.91 years) were included. More than 3.5 million eyes underwent surgery at practices in which the ReSure Sealant was available.

About 93% of cases were routine and the remainder were considered complex. Two-thirds of the cataracts were the nuclear sclerotic type, and the rest were cortical, posterior subcapsular, congenital, and traumatic. Glaucoma procedures were performed concurrently in about 3.5% of cases and vitreous procedures in about 0.5% of cases. Slightly over 20% of patients had a history of diabetes.

The overall incidence of endophthalmitis was 0.633 case per 1,000 surgeries.

The incidence of endophthalmitis was significantly higher after complex procedure compared with routine procedures, i.e., 1.148 vs. 0.592 case per 1,000 surgeries, respectively (p<0.0001).

Based on the use or no use of the ReSure Sealant, no significant difference was found in the incidence of endophthalmitis, i.e., 0.609 vs. 0.660, respectively.

The specific clinical risk factors that the data analysis identified in association with higher incidence rates of endophthalmitis were complex cataract procedures (odds ratio [OR], 1.67); concurrent vitreous procedures (OR, 4.32); traumatic (OR, 4.84), nuclear sclerotic (OR, 1.18), and posterior subcapsular (OR, 1.21) cataracts; and a history of proliferative diabetic retinopathy (OR, 1.53) or diabetic macular edema (OR, 2.04). Male sex (OR, 1.19) and multiethnicity (OR, 2.60) also were significant risk factors. All comparisons were significant (p<0.0001).

“These results provide risk factors for endophthalmitis after cataract surgery from 2016 to 2019 and can identify patients at high risk of developing endophthalmitis after cataract surgery,” Dr. Goldstein concluded.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.